Navigation Links
ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy
Date:2/28/2011

-related signs and symptoms (7.3% with ARCALYST and 7.3% with placebo), and taking more than the recommended dose (5.6% with ARCALYST and 6.4% with placebo).

About GoutGout is a condition that occurs when the bodily waste product, uric acid, is deposited in the joints and/or soft tissues.  In the joints, these uric acid crystals cause inflammation, which leads to pain, swelling, redness, heat, and stiffness in the joints.  Treatment guidelines recommend that patients with elevated uric acid levels who experience multiple gout attacks each year should receive chronic uric acid-lowering therapy, such as allopurinol.  Allopurinol reduces the production of uric acid in the body to prevent the occurrence of gout attacks with long-term use.  Approximately 750,000 gout patients initiate allopurinol therapy each year.  During the first months of allopurinol therapy while uric acid blood levels are being reduced, the break up of the uric acid crystals can result in stimulation of inflammatory mediators, including interleukin-1 (IL-1), resulting in acute flares of joint pain and inflammation.  Anti-inflammatory therapy with colchicine is sometimes used to help prevent these flares.  However, the side effects associated with colchicine, which include diarrhea, abdominal cramps, nausea, and vomiting, can limit patients' adherence to both colchicine and allopurinol treatment.

Rationale for the Clinical Exploration of Use of ARCALYST® (rilonacept) in the Treatment of GoutInterleukin-1 (IL-1) is a protein secreted by infection-fighting cells in the blood and tissues.  In many cases, IL-1 acts as a messenger to help regulate immune and inflammatory responses by attaching to cell-surface receptors in cells that participate in the body's immune system.  In excess, it can be harmful and has been shown to be a key driver of inflammation in a variety of diseases, including gout.  In gout, uric acid crystals stimu
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Mindray Medical Meets 2010 Product Development Targets and Announces Strong 2011 Pipeline
2. New IonWorks Barracuda Automated Patch Clamp System Meets Need for Affordable, Accelerated Screening of Ligand- & Voltage-Gated Ion Channels Via Direct Electrophysiology Assays
3. US Oncology Meets With Leading Pharmaceutical and Biotech Companies to Design Clinical Trials for the Cancer Fighting Drugs of Tomorrow
4. LEO Pharmas PEP005 Meets Primary Endpoint in Phase III Trial for Pre-Cancerous Skin Condition
5. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
6. Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary Endpoint in a Study of Adult Subjects With a History of Grass Pollen Allergies
7. Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
8. Intercept Pharmaceuticals FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
9. Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints
10. MADIT-CRT Trial Meets Primary Endpoint
11. VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB ... composition of matter, biological targets, mechanism of action, methods ... This patent application describes a novel class ... which interfere with the basic homeostatic cellular processes in ...
(Date:1/15/2014)... GENEVA, Ill. , Jan. 15, 2014 The ... a Medical Fitness Center by the Medical Fitness Association, ... centers to achieve their full potential. The Cadence Fitness ... in the western suburbs and second in the Chicagoland ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... – Worldwide Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Analysis Insulin Pumps ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
(Date:4/17/2014)... chronic inflammation in non-cancerous prostate tissue may have nearly ... those with no inflammation, according to results of a ... Kimmel Cancer Center. , The link between persistent inflammation ... high-grade prostate cancer those with a Gleason score ... the most aggressive and rapidly growing prostate cancers. , ...
(Date:4/17/2014)... vaccine brands for children may not be the most ... factors when choosing vaccines, driving the market toward what ... new study by University of Illinois researchers. , "The ... numerous factors," says Sheldon H. Jacobson, a co-author of ... of mathematics at the U. of I. "In an ...
(Date:4/17/2014)... at the University of California, San Diego School of ... who have suffered a recent major loss are more ... adults. , The study is published in this month,s ... . , Because compassionate behaviors are associated with better ... offer insights into ways to improve the outcomes of ...
(Date:4/17/2014)... Hospital Pediatrician-in-Chief Jon McCullers, MD, was recently invited ... of Nature Reviews Microbiology , one of ... a world-renowned infectious disease specialist, and chair of ... Tennessee Health Science Center, analyzed the epidemiology and ... 1968 pandemics, as well as more recent 2009 ...
(Date:4/17/2014)... MAYWOOD, Il. (April 17, 2014) Doctors who ... disease called lymphangioleiomyomatosis (LAM) can face an agonizing ... progression of the disease and help relieve shortness ... lung transplants, and sirolimus can cause potentially fatal ... said pulmonologist Dr. Daniel Dilling, medical director of ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... the Journal of the American Geriatrics Society says that the dying ... // The study found that Arab Americans did not want to ... did not mind it. Hispanic people want to die with dignity ... ,White people did not want to be taken care of by ...
... by non veg items but now roam tomatoes have been found ... three outbreaks in 2004 were caused by this agent. ,The ... havoc. ,The link was establoished when it was ... that was roma tomatoes. ,So the direct culprit was ...
... H. Purcell, NIAID's Laboratory of Infectious Diseases, and Bernard Moss, ... which is found to prevent and treat small pox virus ... there is an increased fear over the use of small ... ,Small pox referral strains are only available in ...
... Professor Michael Beckmann and his colleagues have reported in ... to the lower genital tract reduces// the surgical procedure ... ,Episiotomy is a surgical procedure done in the perineum ... the labor period involved during birthing process to expand ...
... of anxiety-ridden fathers are passed on to the mothers ... many as 65 women were studied by the University ... this conclusion. ,This increased the pain women ... their immediate recovery and factors such as breastfeeding and ...
... dementia at a latter age can be halved as a ... published in the Psychological Medicine//. Cognitive decline can be prevented ... As many as 29,000 people from 22 studies conducted across ... Dr Michael Valenzuela has revealed that where the brain is ...
Cached Medicine News:Health News:Death Wishes Influenced By Ethnicity and Racial Background 2
The ultra micro tip for the new Eppendorf 2000/2100 series ultra micro pipettors provides accurate drawing and dispensing everytime....
... available as both regular and filter tips. ... for more efficient sterilization and are delivered ... date of irradiation. Sterilized Diamond Tips are ... SterilPack Diamond Tips are wrapped in medical ...
This ultra micro tip for the Eppendorf and Nichiryo/BenchMate 0.5-10 L pipettors is perfect for working with low volume....
1000 L, Bulk Recommended for 500 and 1000 L pipettes....
Medicine Products: